As a first step to framework modernization, the Patented Medicines Prices Review Board (PMPRB) is undertaking major consultations regarding possible reform of its Compendium of Policies, Guidelines and Procedures, commonly referred to as “the Guidelines.”
During Phase 1 of this consultation initiative, the PMPRB asked for input on how to rethink the Guidelines in order to improve performance in ensuring that pharmaceutical patent holders do not charge excessive prices. Phase 1 of Rethinking the Guidelines closed on October 31, 2016. Sixty-six Phase 1 public submissions were received and can be found here.
Phase 2 of the consultation process is expected to consist of a public policy hearing before the Board, where stakeholders who commented on the Discussion Paper will have the opportunity to speak to their written submissions. Timelines for Phase 2 will be announced at a later date.
For more information, please click on the following link.